Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Lecomte

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 22, 2018
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trialJ B Bachet, O Lucidarme, C B Levache, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2018
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancerT Aparicio, O Bouché, E Francois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study resultsT Aparicio, O Bouché, J Taieb, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohortT Walter, D Tougeron, E Baudin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 22, 2026
Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II studyG M Camilleri, M A Loriot, G Le Teuff, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2015
Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre studyD Tougeron, G Sickersen, G Mouillet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2018
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter studyJ B Bachet, O Bouché, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)T Aparicio, S Lavau-Denes, J M Phelip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2024
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinomaN Fraunhoffer, P Hammel, T Conroy, et al.
ESMO Open|May 13, 2025
Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II studyE Samalin, L Evesque, A Turpin, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
European Journal of Cancer (Oxford, England : 1990)|October 22, 2018
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trialJ B Bachet, O Lucidarme, C B Levache, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2018
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancerT Aparicio, O Bouché, E Francois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study resultsT Aparicio, O Bouché, J Taieb, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohortT Walter, D Tougeron, E Baudin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 22, 2026
Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II studyG M Camilleri, M A Loriot, G Le Teuff, et al.
European Journal of Cancer (Oxford, England : 1990)|April 13, 2015
Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre studyD Tougeron, G Sickersen, G Mouillet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2018
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter studyJ B Bachet, O Bouché, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2015
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)T Aparicio, S Lavau-Denes, J M Phelip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2024
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinomaN Fraunhoffer, P Hammel, T Conroy, et al.
ESMO Open|May 13, 2025
Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II studyE Samalin, L Evesque, A Turpin, et al.
Pageof 9